S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NYSE:BHVN

Biohaven (BHVN) Stock Price, News & Analysis

$49.54
+1.40 (+2.91%)
(As of 03/1/2024 ET)
Today's Range
$46.25
$51.78
50-Day Range
$40.08
$49.54
52-Week Range
$12.35
$51.78
Volume
1.74 million shs
Average Volume
803,942 shs
Market Capitalization
$3.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.22

Biohaven MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2.7% Downside
$48.22 Price Target
Short Interest
Bearish
10.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Biohaven in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$459,690 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.26) to ($4.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

732nd out of 951 stocks

Pharmaceutical Preparations Industry

321st out of 416 stocks


BHVN stock logo

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Stock Price History

BHVN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biohaven price target raised by $20 at TD Cowen, here's why
Biohaven Ltd BHVN
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biohaven (NYSE:BHVN) PT Raised to $56.00
BHVN Mar 2024 30.000 put
BHVN Mar 2024 50.000 call
BHVN Oct 2024 70.000 call
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
BHVN Jan 2024 50.000 put
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/31/2023
Today
3/03/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
202
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.22
High Stock Price Target
$61.00
Low Stock Price Target
$28.00
Potential Upside/Downside
-2.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-570,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$7.90 per share

Miscellaneous

Free Float
70,255,000
Market Cap
$3.97 billion
Optionable
Optionable
Beta
1.18
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price target for 2024?

8 analysts have issued 1 year price objectives for Biohaven's shares. Their BHVN share price targets range from $28.00 to $61.00. On average, they expect the company's share price to reach $48.22 in the next year. This suggests that the stock has a possible downside of 2.7%.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2024?

Biohaven's stock was trading at $42.80 at the beginning of the year. Since then, BHVN shares have increased by 15.7% and is now trading at $49.54.
View the best growth stocks for 2024 here
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) posted its earnings results on Monday, July, 31st. The company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by $0.14.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stifel Financial Corp (7.76%), Price T Rowe Associates Inc. MD (3.91%), Price T Rowe Associates Inc. MD (3.91%), Point72 Asset Management L.P. (3.10%), Perceptive Advisors LLC (2.15%) and Vanguard Group Inc. (2.07%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, Irina Antonijevic, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric.
View institutional ownership trends
.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 3/3/2024 by MarketBeat.com Staff